๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
NCT06569472Juvenile Dermatomyositis
Chongqing Precision Biotech Co., Ltd
Phase 1
10
Hangzhou
2024-07-02
Recruiting
Study of Clostridioides Difficile in Infants
NCT06788769Clostridioides Difficile Infection
Westlake University
Observational
300
Hangzhou
2024-07-01
Recruiting
A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established
NCT06614179Abdominal Neoplasm
Xiangdong Cheng
Observational
100,000
Hangzhou
2024-07-01
Not yet open
CLIF Correction VS. Conventional Correction Strategy for ASD
NCT05982808Spinal Deformity
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
420
Hangzhou
2024-07-01
Recruiting
Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis
NCT06514339Sepsis
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase EARLY_PHASE1
410
Hangzhou
2024-07-01
Active, closed
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
NCT06709144Colon Cancer
Haixing Ju, MD
Phase 3
896
Hangzhou
2024-07-01
Active, closed
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
NCT06449586Hematologic Malignancy
DrugLetermovir
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
NCT06461624Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1
15
Hangzhou
2024-07-01
Recruiting
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
NCT06530732Alzheimer's Disease
DrugLecanemab
Zhejiang Provincial People's Hospital
Phase 3
60
Hangzhou
2024-07-01
Active, closed
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer
NCT06465563Biliary Tract Cancer
DrugsSHR-8068·Adebrelimab·Gemcitabine·Cisplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
93
Nanjing, Hangzhou
2024-07-01
Recruiting
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
NCT07153848Alzheimer Disease
First Affiliated Hospital of Zhejiang University
Observational
400
Hangzhou
2024-07-01
Recruiting
Study on Clostridium Difficile Infection in Infants
NCT06703918Clostridium Difficile Infection
First People's Hospital of Hangzhou
Observational
150
Hangzhou
2024-07-01
Recruiting
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597Generalized Myasthenia Gravis
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
NCT06705127HR-positive,HER2-negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou
2024-07-01
Recruiting
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
NCT06741553Alzheimer Disease, Mild Cognitive Impairment (MCI)
DrugLecanemab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2024-06-28
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·MFOLFOX6·Trastuzumab emtansine
Boehringer Ingelheim
Phase 1/2
768
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
NCT06504940Marginal Zone Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 2
69
Hangzhou
2024-06-28
Recruiting
Intraventricular Administration of Intracranial Infections Caused by ๏ผˆCarbapenem-resistant Gram-negative Bacilli๏ผ‰CRGNB
NCT06595979Intracranial Infections
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
222
Hangzhou, Ningbo, Wenzhou
2024-06-25
Recruiting
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
NCT06483282Small Cell Lung Cancer Limited Stage
DrugsApatinib Mesylate·Etoposide·Adebrelimab·Carboplatin
Jin Ying
Phase 2
38
Hangzhou
2024-06-21
Recruiting
The Peripheral Blood Multi-Omics Study on Sleep Loss
NCT06492109Sleep Deprivation, Aging, Alzheimer Disease, Healthy Lifestyle
First Affiliated Hospital of Zhejiang University
Not applicable
60
Hangzhou
2024-06-20
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
52
Hangzhou
2024-06-20
Not yet open
Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy
NCT06442605Leiomyoma, Uterine
First People's Hospital of Hangzhou
Not applicable
22
Hangzhou
2024-06-20
Active, closed
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531Generalized Pustular Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
NCT06537115Sarcopenia
Zhejiang Provincial People's Hospital
Phase 4
450
Hangzhou, Huzhou, Taizhou, Zhoushan
2024-06-16
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
NCT06611813HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, รœrรผmqi, Xi'an
2024-06-11
Recruiting
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292Acute Myeloid Leukemia
DrugsLisaftoclax·Azacitidine
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06881498Bone Tumor, Acute Normovolemic Hemodilution, Goal-Directed Fluid Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
32
Hangzhou
2024-06-07
Recruiting
The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06459141Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
150
Hangzhou
2024-06-07
Recruiting
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
NCT06976177Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 2
310
Hangzhou
2024-06-07
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Recruiting
A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection Surgery
NCT06434389Hypofibrinogenemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2024-06-01
Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
DrugTislelizumab
Zhejiang Cancer Hospital
Phase 2
191
Hangzhou
2024-06-01
Recruiting
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
NCT06445881Non Small Cell Lung Cancer, Perioperative Complication
First Affiliated Hospital of Zhejiang University
Phase 2
60
Hangzhou
2024-06-01
Recruiting
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
NCT06346912Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
Zhejiang University
Phase EARLY_PHASE1
20
Hangzhou
2024-05-30
Recruiting
The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia
NCT06867315Benign Prostatic Hyperplasia
First Affiliated Hospital of Zhejiang University
Not applicable
10
Hangzhou
2024-05-29
Recruiting
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06417008Non-Squamous Non-Small Cell Lung Cancer
DrugsHS-20117·Aumolertinib
Hansoh BioMedical R&D Company
Phase 2/3
1,080
Tianjin, Hangzhou
2024-05-28
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082Hematological Malignancies
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
Clinical Effects of Keratinized Mucosa Augmentation Around Dental Implant With Free Gingival Graft in Different Surgical Timing at Mandibular Posterior Sites
NCT07088172Edentulous Alveolar Ridge In Mandible
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
24
Hangzhou
2024-05-23
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Lurbinectedin·Ifinatamab Deruxtecan·Topotecan
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
Predictive Effect of TGF-ฮฒ and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients
NCT06426953Diabetes, Postoperative Delirium
Xie Kangjie
Observational
180
Duyun, Hangzhou
2024-05-20
Recruiting
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
NCT06424899Non Small Cell Lung Cancer
DrugAdebrelimab
Zeng Jian
Phase 2
92
Hangzhou
2024-05-19
Recruiting
Screening of Biomarkers and Related Mechanisms for RIX
NCT07170358Xerostomia Due to Radiotherapy (Disorder)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50
Nanjing, Hangzhou
2024-05-17
By invitation
Electroencephalogram Characteristics of Surgical Anesthetized Patients and Postoperative Dilirium
NCT06394778Electroencephalogram, Postoperative Delirium (POD)
First Affiliated Hospital of Zhejiang University
Observational
375
Hangzhou
2024-05-13
Recruiting
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06394492Ovarian Cancer
DrugsSHR-A1921·Topotecan·Doxorubicin·Paclitaxel
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
440
Beijing, Hangzhou
2024-05-10
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,700
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-05-06
Recruiting
Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With "Dao qi Tong Luo" Based on the Theory of "Connecting the Two Ears to the Brain"
NCT06401993Tinnitus
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
87
Hangzhou
2024-05-04
Recruiting
Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
NCT06728891Gastric Carcinoma
Jichao Qin
Observational
100
Hangzhou
2024-05-01
Recruiting
A Functional Near- Infrared Spectroscopy Study on the Brain Activation Characteristics of Stroke Patients During Mirror Movement
NCT07509944Stroke, Upper Limb Function
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
25
Hangzhou
2024-05-01
Recruiting
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
NCT06379087Non-Small Cell Lung Cancer
Ji Yongling
Phase 2
20
Hangzhou
2024-05-01
Recruiting
Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
NCT06728878Gastric Cancers
Jichao Qin
Observational
150
Hangzhou
2024-05-01
Recruiting
Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer
NCT06385717Esophagus Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2024-05-01
Recruiting
the Multi-modal Evaluation of Agitation in Critically Ill Patients Based on Remote Video-Ultra-sensitive Detection Wave
NCT06543602Critically Ill Patients
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
580
Hangzhou, Hanzhou
2024-05-01
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
By invitation
Based on the Data from the Zhejiang Emergency Center, Explore the Independent and Interactive Effects of the Association Between Meteorological Factors and Air Pollution and the Number of Emergency Personnel, Identify the Relevant Vulnerable Population Characteristics, Sensitive Disease Types
NCT06798987Fig. Impetuous
Li hengjie
Observational
1,500,000
Hangzhou
2024-05-01
Recruiting
Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
NCT06736847Gastric Carcinoma
Jichao Qin
Observational
200
Hangzhou
2024-05-01
Recruiting
Application of Machine Learning Based on fNIRS in Predicting Acupuncture's Efficacy in Treating Tinnitus
NCT06364670Tinnitus
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
500
Hangzhou
2024-05
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
NCT06217861Glutaric Acidemia Type I, Glutaric Aciduria Type I
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Hangzhou
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLY3650150
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Not yet open
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
NCT06374901Gastric Cancer
DrugTislelizumab
Xiangdong Cheng
Phase 2
134
Hangzhou
2024-04-25
Recruiting
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
NCT06718309Non-Small Cell Lung Cancer
First People's Hospital of Hangzhou
Phase 2
40
Hangzhou
2024-04-24
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
DrugsOsimertinib·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT06279923Autoimmune Diseases
Zhejiang University
Phase EARLY_PHASE1
45
Hangzhou
2024-04-15
Recruiting
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT06251947Ovarian Cancer, Cervical Cancer
DrugEfbemalenograstim alfa
Shandong University
Phase 2
83
Changsha, Nanjing, Jinan, Qingdao, Taiyuan, Hangzhou
2024-04-15
Active, closed
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
NCT06341114Advanced Solid Tumors
DrugBAT1308
Bio-Thera Solutions
Phase 1/2
112
Hangzhou
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Dato-DXd·Rilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
NCT06361329ETP-ALL
First Affiliated Hospital of Zhejiang University
Phase 3
81
Hangzhou
2024-04-03
Recruiting
Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease
NCT06431711Cerebral Small Vessel Diseases, Retinal Ischemia, Choroid; Injury
Zhejiang Provincial People's Hospital
Observational
2,400
Hangzhou
2024-04-01
Recruiting
the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in PSCI
NCT06313866Stroke
Hangzhou Medical College
Not applicable
220
Hangzhou
2024-04-01
Recruiting
Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)
NCT06451887Endovascular Therapy, Brain Edema, Prediction Model, Ischemic Stroke
Zhejiang Provincial People's Hospital
Observational
1,950
Hangzhou
2024-04-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
579
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
Septal Ablation for Obstructive HCM
NCT06277960Hypertrophic Obstructive Cardiomyopathy (HOCM)
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
20
Hangzhou
2024-03-28
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
DrugsEquecabtagene Autoleucel·Bortezomib·Pomalidomide·Daratumumab
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
NCT06642857Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Xiangdong Cheng
Observational
150
Hangzhou
2024-03-25
Recruiting
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
NCT06292689Vulvar and Vaginal Cancer
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2024-03-22
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
By invitation
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
NCT06438679Dermatomyositis
DrugTofacitinib
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
133
Hangzhou
2024-03-19
Recruiting
Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
NCT06385106Alzheimer Disease
First Affiliated Hospital of Zhejiang University
Not applicable
30
Hangzhou
2024-03-16
Recruiting
Research on Anesthesia Depth Control Strategy Based on Continuous and Non-invasive Monitoring of Exhaled Breath
NCT07272044Anesthesia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2024-03-16
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
By invitation
Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder
NCT06765629Overactive Bladder (OAB)
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
200
Hangzhou
2024-03-09
Recruiting
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788Leukemia, Myeloid, Acute
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2
24
Guangzhou, Hangzhou
2024-03-07
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Recruiting
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
NCT06314334Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
DrugsGelad·P-Gemox·Pegaspargase·Tislelizumab
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Active, closed
Multicenter Study on the Use of Intraoperative OCT in the Diagnosis and Management of Lens Diseases
NCT07741370Lens Diseases, Cataract, Age-related Cataract, Complicated Cataract
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,200
Hangzhou
2024-03-01
Active, closed
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
NCT06294678Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
NCT06272214Adjuvant Radiotherapy
Zhejiang Cancer Hospital
Phase 2
146
Hangzhou
2024-03-01
Active, closed
Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative Recurrence
NCT07328828RFS
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
20
Hangzhou
2024-03-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405Respiratory Synctial Virus Infections
DrugZiresovir
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Sanya, Shanghai, Shenyang
2024-02-29
Rows per page Showing 1101–1200 of 1812
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=12

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.